Molecular Dx Significance 5/10

Multi-biomarker model quantifies prolonged diagnostic delays in late HIV-1 infection

Investigators applied a multi-biomarker model integrating CD4 counts, pol polymorphism counts, pol next-generation sequencing diversity, and HIV-1 limiting-antigen avidity assays to estimate time since infection in 344 newly diagnosed individuals in Sweden. The analysis showed that 41% of all cases were diagnosed within one year of infection, while over 60% of late diagnoses remained undiagnosed for more than three years. The study demonstrates that multi-biomarker estimation can effectively quantify diagnostic delays and guide targeted screening policies for populations with higher late-presentation rates.

The original study

Beyond CD4 counts: Multi-biomarker assessment of estimated time since HIV-1 infection and risk factors for late diagnosis.

Authors
Smith K, Locke M, Andersson E, Broddesson S, Carlander C, Yilmaz A, et al.
Journal
HIV medicine
Type
Journal Article
PMID
42836675
Read the original study →

Original abstract

BACKGROUND: Late diagnosis (LD) of HIV, defined as CD4 count <350 cells/μL or AIDS at diagnosis, remains a substantial public health challenge, with half of individuals in Europe diagnosed late. How long these individuals have lived with HIV remains unclear. We applied a multi-biomarker model (MBM) to estimate the time since infection (ETI) in newly diagnosed individuals classified as LD. METHODS: We conducted a prospective cohort study of newly diagnosed people with HIV in Sweden between November 2017 and December 2022. Individuals were classified as LD or non-LD according to an updated consensus definition. We applied an MBM combining CD4 count, pol polymorphism counts, pol next-generation sequencing diversity, HIV-1 limiting-antigen avidity assay and last negative HIV test to probabilistically derive ETI distributions. RESULTS: More than half (52.4%) were classified as LD. Risk factors for LD included age >50 years (adjusted odds ratio (aOR) 2.94, 95% CI 1.42-6.09), origin in Asia and Pacific (aOR 4.53, 95% CI 1.81-11.32) and HIV acquisition in Asia and Pacific (aOR 2.28, 95% CI 1.08-4.83). Men who have sex with men had reduced risk of LD versus persons with heterosexual acquisition (aOR 0.38, 95% CI 0.22-0.64). ETI in 344 individuals revealed diagnostic delays; 41% (95% CrI 36.7-46.0) were diagnosed within 1 year: 71% of non-LDs (CrI 95% 65.0-77.7) versus 12% of LDs (95% CrI 8.4-16.2). Among LDs, over 60% remained undiagnosed beyond 3 years. CONCLUSIONS: Multi-biomarker ETI reveals that most HIV-1 infections remain undiagnosed for over 1 year. The updated LD definition correlates better with time since infection and ETI distributions show substantial diagnostic delays. Expanded testing strategies targeting heterosexual and older populations are urgently needed.